Jci_page_head_homepage_01 Jci_page_head_homepage_02
Stephan Wueest, Reto A. Rapold, Desiree M. Schumann, Julia M. Rytka, Anita Schildknecht, Ori Nov, Alexander V. Chervonsky, Assaf Rudich, Eugen J. Schoenle, Marc Y. Donath, Daniel Konrad
Published in Volume 120, Issue 1
J Clin Invest. 2010; 120(1):191–202 doi:10.1172/JCI38388
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 5
AFasKO mice are protected from HFD-induced deteriorations in glucose metabolism.

(A) 14C-d-glucose incorporation into isolated perigonadal adipocytes from WT (Fasfl/fl;Fabp4-Cre–/–) and AFasKO (Fasfl/fl;Fabp4-Cre+/–) mice was determined in the absence or presence of insulin. Results are expressed relative to basal uptake and represent mean ± SEM of 5 independent experiments performed in triplicate. *P < 0.05 (Student’s t test). Intraperitoneal glucose (B) and insulin (C) tolerance tests (ipGTT and ipITT) were performed in WT (filled circles) and AFasKO (open circles) mice. Inset graphs in B and C depict the respective analysis of the area under the curve. Results are mean ± SEM of 8–10 animals per group. *P < 0.05, **P < 0.01 (Student’s t test). (D) Steady-state glucose infusion rates during hyperinsulinemic-euglycemic clamps. Results are mean ± SEM of 3–4 animals per group. **P < 0.01 (Student’s t test). (E) Plasma FFA levels in HFD-fed WT and AFasKO mice before and at the end of a euglycemic-hyperinsulinemic clamp are depicted. Results are mean ± SEM of 3 animals per group. *P < 0.05 (Student’s t test).